Interferon stimulated gene 15 (ISG15) deficiency in humans leads to severe 23 interferonopathies and mycobacterial disease, the latter being previously attributed to 24 its extracellular cytokine-like activity. Here, we demonstrate a novel role for secreted 25 ISG15 as an IL-10 inducer, unique to primary human monocytes. Employing ex vivo 26 systems analysis of human transcriptome datasets, we observed a significant 27 correlation of ISG15-induced monocyte IL-10 and lymphocyte IFNγ expression. This 28 effect was associated with p38 MAPK and PI3K signalling in healthy volunteers. The 29 specificity and MAPK/PI3K-dependence of ISG15-induced monocyte IL-10 30 production was confirmed in vitro using CRISPR/Cas9 knockout and 31 pharmacological inhibitors. Moreover, this ISG15/IL10 axis was amplified in leprosy 32 but disrupted in human active tuberculosis (TB) patients. Importantly, ISG15 strongly 33 correlated with inflammation and disease severity during active TB. In conclusion, 34 this study identifies a novel anti-inflammatory ISG15/IL-10 myeloid axis that is 35 disrupted in active TB, revealing a potential biomarker for disease severity in this 36 major human disease. 37 38 39
Introduction 40
Type one interferons (IFN-I) exert most of their functions by inducing the expression 41 of interferon-stimulated genes (ISGs). To date, over 300 ISGs have been described 42 To test whether endogenously produced ISG15 stimulates IL-10 synthesis, a co-128 culture experiment was set up using a lung epithelial cell line, A549, as a source of 129 ISG15 (Wang et al., 2017b) . For these assays, an ISG15-knockout (KO) A549 cell 130 line was generated using CRISPR/Cas9 technology (Supplementary Figure 1B, Fig. 2K ), thus corroborating with our in 145 vitro results ( Fig. 2A-D) . Consistent with a previous study (Tamassia et al., 2013) , 146 low or undetectable IL10 transcripts in human neutrophils (Fig. 2K ) are explained by 147 the inactive chromatin configuration of the IL10 locus in these cells. Together, this set 148 of results suggests a role for extracellular rather than intracellular ISG15 as inducer of 149 monocyte-derived IL-10 (this study) and NK-derived IFNγ (Bogunovic et al., 2012) . 150
Since the unique susceptibility of ISG15-deficient children to low virulence 151 mycobacteria has underscored a role for extracellular ISG15 (Bogunovic et al., 2012) , 152
we performed a systems analysis approach to gain insights on the possible influence 153 of ISG15/IL-10 axis during mycobacterial exposure in humans. family members were up-regulated in both latent and active TB ( Figure 3A) . 168
However, PIK3CA (PI3Kalpha) levels were up-regulated in active TB and down-169 regulated in latent TB. In this scenario MAPK14 (p38) expression levels were 170 significantly and positively correlated to ISG15 levels ex vivo ( Figure 3B ). 171
Additionally, MAPK3 (MAP3K/ERK1) levels were positively correlated to IL10 172 ( Figure 3C ) and negatively correlated to IFNG transcript levels ( Figure 3D ). Finally, 173 PIK3CA and PIK3CB (PI3Kbeta) transcripts were negatively correlated to IL10 174 expression levels ( Figure 3E 
Material and methods 358
Reagents 359
ISG15 was purchased from Boston Biochem and tested for endotoxins by R&D 360
Systems (endotoxin value for lot #DBHF0614021 is <0.00394 EU/µg). LAL assay 361 (Lonza) was performed according to the manufacturer's instruction and the endotoxin 362 level of recombinant ISG15 was below the detection threshold. Pro-ISG15 (UL-615) 363 was also purchased from Boston Biochem. E. coli LPS (strain O111:B4) (Invivogen) 364 was used as a positive control for IL-10 production in human PBMCs and monocytes. 365 P38 kinase inhibitors SB203580 and SB220025 (Calbiochem) were used at 10 µM, 366 MEK1/2 inhibitor U0126 (Cell Signaling) at 50 µM and PI3K inhibitor Ly294002 367 (Cell Signaling) was at 50 µM. Solvent (DMSO, medium) was used as negative 368 control and chloroquine (Sigma, 5µg/mL), a DNA-PKC/TLR endosomal signalling 369 inhibitor, was used as an additional negative control. 370
371

Primary human cells 372
Human PBMCs were separated from healthy individuals using Ficoll-paque (GE) 373 according to manufacturer's instructions. Briefly, blood was collected in heparin-374 containing tubes, and gently mixed 1:1 with saline solution and gently mixed before 375 being added over one volume of Ficoll-paque reagent. The gradient was centrifuged 376
for 35 minutes at 400 x g, 18˚C. PBMCs were harvested and washed once with 45 mL 377 of saline solution for 10 min at 400 x g, 18˚C. Subsequently, cell pellet was 378 suspended and washed twice with 5 mL of saline solution for 10 min at 200 x g, 18˚C 379
to remove platelets. The remaining cell pellet was suspended to the desired density in 380 RPMI 1640 (Gibco) supplemented with 5% foetal calf serum (Hyclone), 2mM L-381 glutamine (Gibco), 1 mM sodium pyruvate (Gibco), 25 mM HEPES (Gibco), 100 382 U/mL penicillin and 100 µg/mL streptomycin (Gibco). Cells were plated as described 383 in each experiment. Human primary monocytes (CD14 + cells) were separated from 384 PBMCs using CD14 microbeads (Miltenyi Biotec) according to manufacturer's 385 instructions with the exception of the MACS buffer, which was prepared using 3% Figure 1B) . comprising ex vivo and in vitro whole blood, total PBMCs, purified leukocyte subsets, 505 non-leukocyte human primary cells and skin biopsies (leprosy patients, healthy 506 controls and cutaneous leishmaniasis as non-mycobacterial infectious control). Novel 507 datasets were generated for both whole blood and PBMCs from healthy controls and 508 individuals infected with other non-mycobacterial intracellular pathogens 509 (Leishmania, HIV-1, HTLV-1). PBMCs were isolated as above and immediately 510 frozen in Trizol to preserve RNA integrity. Following Trizol extraction, total RNA 511 was further purified using an RNeasy kit according to the manufacturer's protocol 512 (QIAGEN, Venlo, Netherlands). Affymetrix Whole Genome microarray analysis was 513 performed by the VIB Nucleomics Facility (Leuven, Belgium) using a GeneChip 
Enrichment analysis 522
The Ingenuity Pathway Analysis (IPA) program was used to perform the initial 523 pathway/function level analysis on genes determined to be differentially expressed in 524 the microarray analysis (Ingenuity Systems, Red Wood City, CA). Uncorrected p-525 values and absolute fold-changes were used with cut-offs of p<0.05. Based on a 526 scientific literature database, the genes were sorted into gene networks and canonical 527 pathways, and significantly overrepresented pathways were identified. Further 528 enrichment analysis was performed, including Gene Ontology (GO) term enrichment 529 using the WEB-based GEne SeT AnaLysis Toolkit (WebGestalt), KEGG pathway 530 enrichment using the pathway database from the Kyoto Encyclopedia of Genes and 531
Genomes and transcription factor target enrichment using data from the Broad 532 
FWO (G0D6817N). 557
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